Treatment Information

Back

Lung Cancer treatment details. Chemotherapy.

Hygeia Hospital, Athens, Greece.

Survival: monthsCountry:Greece
Toxiciy Grade:5City/State/Province:Athens
Treatments:ChemotherapyHospital:Hygeia Hospital
Drugs:Journal:Link
Date:Jan 2008

Description:

Patients: This phase III study involved 452 patients with advanced, inoperable, non-small-cell lung cancer. The median age was 63, ranging from 36 to 83 years of age. The majority of patients were men.

Treatment: These patients were treated with paclitaxel and gemcitabine, or with carboplatin and gemcitabine. These are chemotherapy drugs.

Toxicity: Three patients died, two from pancytopenia (not having enough red and white blood cells) and one from sepsis febrile neutropenia. Neutropenia was the most common grade 4 toxicity in patients treated with carboplatin and gemcitabine, occurring in 14.2% of patients. In the group treated with paclitaxel and gemcitabine, the most common grade 4 toxicity was thrombocytopenia, reported in 15.1% of patients. Overall, hematological toxicites were more common in the patients treated with carboplatin and gemcitabine.

Results: The median overall survival of patients treated with paclitaxel and gemcitabine was 9.97 months, and for those treated with carboplatin and gemcitabine, the median overall survival was 10.49 months.

Correspondence: Dr. P.A. Kosmidis



Back